Rheumatoid Arthritis Flashcards

1
Q

associated alleles with ra

A
  • hla drb1
  • ptpn22
  • padi4
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

pathophysio of ra

A

read

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

pathological hallmarks of ra

A
  • synovial inflammation and proliferation
  • focal bone erosions
  • thinning or articular cartilage
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

what is a pannus

A

mass of edematous synovium, inflammatory cells, granulation tissue, and fibroblasts

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

classic clinical picture

A

chronic inflammatory symmetric polyarthritis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

inflammatory features

A
  • tender, warm, swollen
  • morning stiffness
  • symmetric
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

joints involved

A
  • small joints of hands and feet
  • wrists, metacarpal phalangeal joints, pip
  • flexor tendon tenosynovitis
  • dips spared
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

ra specific deformities

A
  • ulnar deviation
  • boutonniere deformity
  • swan neck deformity
  • zigzag deformity
  • “piano key movement” of ulnar styloid
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

natural history

A
  • early: metatarsophalangeal joint pain
  • ankle and mid-tarsal region
  • atlantoaxial of cervical spine
  • late: large joints (knees and shoulders)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

most common extra articular symptoms

A
  • weight loss
  • fever
  • fatigue
  • malaise
  • depression
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

risk factors for systemic inolvement

A
  • cigarette smoking
  • early onset of significant physical disability
  • (+) rf or anti-ccp antibodies
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

common hematologic manifestation

A
  • anemia of chronic disease

- felt’s syndrome: neutropenia, splenomegaly, nodular rheumatoid arthritis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

renal and cardiac manifestation

A
  • membranous nephropathy
  • secondary amyloidosis
  • ischemic heart disease
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

differentials for ra

A
  • infectious/ viral arthritis (chikungunya, dengue, hep b)
  • sle
  • psoriatic arthritis
  • other ct/ autoimmune diseases
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

t/f sle results in erosions and irreversible deformities

A

false

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

ra vs osteoarthritis

17
Q

clinical findings in oa

A
  • short morning stiffness, worsened by effort
  • bouchard’s nodes
  • heberden’s nodes
  • (-) rf and anti-ccp
18
Q

serology

A
  • rf: negative in first year
  • acpa
  • elevated esr and crp
19
Q

synovial fluid analysis

A
  • 5,000-50,000 wbc/ul with neutrophilic predominance
  • decreased string sign
  • most useful for confirming inflammatory arthritis or execluding infection
20
Q

plain xray findings

A
  • periarticular osteopenia or no changes

- soft tissue swelling, symmetric joint space loss, subchondral erosions

21
Q

mri findings

A
  • early detection

- greatest sensitivity for synovitis and joint effusions

22
Q

uts and doppler

A
  • detect more erosions

- detect synovitis and increased vascularity (= inflammation)

23
Q

2010 acr/eular classification for ra

A

joint: 1 large, 2-10 large, 1-3 small, 4-10 small, >10

serology
acute phase reactants (crp and esr)
duration (6 wks)

6 = definite ra

24
Q

approach to treatment

25
remission
- tender joint count less/= 1 - swollen joint count less/= 1 - crp less/= 1 - patient global assessment less/= 1 OR simplified DAI less/= 3.33
26
factors for improved outcome
- methrotrexate = toc for early ra | - combination dmard > methotrexate
27
pharmacologic treatment
- nsaids - glucocorticoids - dmards - biological dmards
28
glucocorticoids
- low to moderate doses before dmard therapy | - high dose for severe
29
risks to chronic glucocorticoids
- osteoporosis - infection - cushing's - gastritis
30
dmards
- methotrexate - leflunomide - hydroxychloroquine - sulfasalaizine - others
31
biological dmards
- tnf: infliximab, adalimumab, goli, certolizu, etanercept - cd28/cd80/cd86: abatacept - ccd20: rituximab - il6: tocilizumab, sarilumab - jak: tofacitinib, barcitinib
32
contraindications for tnf targeting
- chronic infection (hep b/c) | - class 3/4 heart failure
33
___ have spontaneous remission within 6 mos
10%
34
clinical course
- majority have persistent and progressive disease | - 2x higher mortality (ischemic heart disease, infection)
35
risk factors for shortened lifie expectance
- systemic extraarticular involvement - low functional capacity - low socioeconomic status - low education - chronic prednisone use